A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept
Divya Koura(University of California San Diego), Dimitrios Tzachanis(Dana-Farber Cancer Institute), James K. Mangan(UC San Diego Health System), Joseph Maroge(University of California San Diego), James Mirocha(Cedars-Sinai Medical Center), Carolyn Mulroney(University of California San Diego Medical Center), Ah‐Reum Jeong(University of California San Diego), Kaitlyn C. Dykes(University of California San Diego), Kimberly McConnell(University of California San Diego), Caitlin Costello(University of California San Diego), Michelle Padilla(University of California San Diego), Aaron M. Goodman(University of California San Diego), Edward D. Ball(Sheba Medical Center), Ayad Hamdan(University of California San Diego), Gerald P. Morris(University of California San Diego), Paula Ogrodnik(University of California San Diego), Tiffany Tanaka(UC San Diego Health System)
Cited by 7
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
|Nature Reviews Clinical Oncology|2016|464